看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 0.5x - 0.6x | 0.5x |
| Historical Pb Multiple | 0.4x - 0.8x | 0.6x |
| Fair Value | ₩10,214 - ₩11,289 | ₩10,752 |
| Upside | 26.9% - 40.2% | 33.6% |
| Benchmarks | - | Full Ticker |
| Dong-A ST Co., Ltd. | - | KOSE:A170900 |
| Huons Global Co., Ltd. | - | KOSDAQ:A084110 |
| Kyung Dong Pharmaceutical Co., Ltd. | - | KOSDAQ:A011040 |
| Dongwha Pharm.Co.,Ltd | - | KOSE:A000020 |
| JW Lifescience Corporation | - | KOSE:A234080 |
| Jeil Pharma Holdings Inc | - | KOSE:A002620 |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| A170900 | A084110 | A011040 | A000020 | A234080 | A002620 | |||
| KOSE:A170900 | KOSDAQ:A084110 | KOSDAQ:A011040 | KOSE:A000020 | KOSE:A234080 | KOSE:A002620 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | -0.7% | -22.9% | -9.4% | 14.9% | NM- | ||
| 3Y CAGR | NM- | 74.1% | -24.4% | -32.2% | 50.5% | NM- | ||
| Latest Twelve Months | -111.0% | -32.8% | 126.4% | -79.7% | 56.3% | -214.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 1.9% | 8.3% | 3.3% | 6.8% | 10.4% | -5.2% | ||
| Prior Fiscal Year | 1.7% | 5.1% | -12.7% | 7.6% | 13.6% | -2.0% | ||
| Latest Fiscal Year | -0.2% | 3.2% | 2.8% | 1.2% | 19.8% | -6.6% | ||
| Latest Twelve Months | -0.2% | 3.2% | 2.8% | 1.2% | 19.8% | -6.6% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 2.6% | 2.9% | 2.3% | 6.2% | 14.5% | -9.0% | ||
| Prior Fiscal Year | 1.7% | 7.9% | -8.5% | 7.5% | 18.8% | -4.9% | ||
| Latest Twelve Months | -0.2% | 5.0% | 2.4% | 1.5% | 24.4% | -16.3% | ||
| Next Fiscal Year | 3.3% | 5.5% | 1.0% | 6.0% | 26.0% | -4.2% | ||
| Two Fiscal Years Forward | 4.7% | 5.5% | 3.5% | 8.0% | 22.0% | -4.4% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 0.6x | 0.8x | 0.8x | 0.4x | 0.8x | 0.2x | ||
| Price / LTM EPS | -335.3x | 23.9x | 28.3x | 30.7x | 4.0x | -2.4x | ||
| Price / Book | 0.6x | 1.2x | 0.7x | 0.5x | 0.9x | 0.4x | ||
| Price / Fwd Book | 0.6x | 1.2x | 0.7x | 0.4x | 0.7x | 0.4x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.5x | 0.7x | 1.2x | |||||
| Historical P/B Ratio | 0.4x | 0.6x | 0.8x | |||||
| Selected P/B Multiple | 0.5x | 0.5x | 0.6x | |||||
| (x) Book Value | 306,950 | 306,950 | 306,950 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | A170900 | A084110 | A011040 | A000020 | A234080 | A002620 | |
| Value of Common Equity | 412,803 | 617,527 | 153,838 | 170,465 | 174,821 | 123,577 | |
| (/) Shares Outstanding | 9.2 | 12.2 | 26.9 | 27.7 | 15.5 | 15.4 | |
| Implied Stock Price | 45,050.00 | 50,700.00 | 5,710.00 | 6,150.00 | 11,290.00 | 8,050.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 45,050.00 | 50,700.00 | 5,710.00 | 6,150.00 | 11,290.00 | 8,050.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |